PREVENTION OF SURGICAL ADHESIONS

• US 20100222371A1
• Filed: 11/18/2009
• Published: 09/02/2010
• Est. Priority Date: 11/20/2008
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Greene, Arin K., Puder, Mark
• Application Number:
  US12/620,665
• Publication Number:
  US 20100222371A1
• Time in Patent Office: Days
• US Class Current: 514/266.400
• CPC Class Codes: A61K 31/404 Indoles, e.g. pindolol
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention relates to methods for treatment (particularly the prevention or suppression) of formation or reformation of adhesions, particularly in the peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma. The invention provides methods useful for inhibiting, suppressing or ameliorating adhesion formation in mammals, including humans wherein an individual is administered a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib. The invention applies to human and veterinary applications. The inventive method has been shown to be especially effective in preventing adhesion formation in the peritoneum following surgery.

Claims

1. A method of treating, preventing, or minimizing adhesion formation during or following a surgical procedure comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib.

4. The method of claim 1, wherein the adhesion is between organ or tissue surfaces.

6. The method of claim 1, wherein the surgical procedure is cosmetic or by incision.

7. The method of claim 6, wherein the surgical procedure comprises implanting a breast implant, an implant used in cosmetic surgery, an abdominal implant, a urologic implant, or an orthopedic implant.

8. The method of claim 1, wherein said compound is administered to said patient before surgery.

9. The method of claim 1, wherein said compound is administered by applying to organ surfaces during surgery.

10. The method of claim 1, wherein said compound is administered after surgery.

11. The method of claim 1, wherein said compound is administered by use of a suppository.

2. A method of treating or preventing benign hypertrophic tumors comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib.

3. A method of treating, preventing, or minimizing scar formation during or following a surgical procedure comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib.

5. The method of claim 3, wherein the scar comprises a keloid formation.